CHKB-Related Intellectual Disability & Neurodevelopment Delay

CHKB-related intellectual disability and neurodevelopmental delay are defining features of congenital megaconial muscular dystrophy, affecting approximately 96% of diagnosed individuals. Despite typically normal structural brain MRI findings, children experience significant challenges in cognitive development, speech acquisition, and learning ability. These neurodevelopmental outcomes arise from impaired phospholipid biosynthesis and downstream metabolic dysfunction that disrupt neuronal and neuromuscular systems.

Clinically, children often present with delayed speech or absent speech, global developmental delay, reduced processing speed, impaired memory, and difficulty with problem-solving and academic tasks. Early hypotonia and motor delay frequently compound cognitive challenges by limiting exploration, mobility, and opportunities for developmental progress.

Although no curative treatments exist, early intervention programs, speech therapy, occupational therapy, and individualized educational plans can help support functional gains. Families also benefit from neuropsychological evaluation to guide learning strategies and long-term planning.

CHKB-related neurodevelopmental impairment represents a substantial and lifelong burden, highlighting an urgent need for therapeutic approaches that target the underlying cellular dysfunction contributing to cognitive and speech delays.